A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.

Abstract

Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1-3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors evaluated 5 once daily (QD) surufatinib doses (3 + 3 design) to identify maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and evaluate safety and efficacy at the RP2D in 4 disease-specific expansion cohorts including pancreatic neuroendocrine tumors [pNET] and extrapancreatic NETs [epNET]. MTD and RP2D were 300 mg QD (escalation [n = 35]); 5 patients (15.6%) (Dose Limiting Toxicity [DLT] Evaluable Set [n = 32]) had DLTs. Pharmacokinetics were dose proportional. Estimated progression-free survival (PFS) rates at 11 months were 57.4% (95% confidence interval [CI]: 28.7, 78.2) and 51.1% (95% CI: 12.8, 80.3) for pNET and epNET expansion cohorts, respectively. Median PFS was 15.2 (95% CI: 5.2, not evaluable) and 11.5 (95% CI: 6.5,11.5) months. Response rates were 18.8% and 6.3%. The most frequent treatment-emergent adverse events (both cohorts) were fatigue (46.9%), hypertension (43.8%), proteinuria (37.5%), diarrhea (34.4%). Pharmacokinetics, safety, and antitumor efficacy of 300 mg QD oral surufatinib in US patients with pNETs and epNETs are consistent with previously reported studies in China and may support applicability of earlier surufatinib studies in US patients. Clinical trial registration: Clinicaltrials.gov NCT02549937.

• Authors: Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li, Max W Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Scott Paulson
• Journal: Investigational new drugs (Invest New Drugs) Vol. 41 Issue 3 Pg. 421-430 (Jun 2023) ISSN: 1573-0646 [Electronic] United States
• PMID: 37074571 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Vascular Endothelial Growth Factor Receptor-1
• surufatinib
• Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor A
• Protein Kinase Inhibitors

Topics

• Humans
• Neuroendocrine Tumors (drug therapy, pathology)
• Vascular Endothelial Growth Factor Receptor-1
• Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor A
• Neoplasms (pathology)
• Protein Kinase Inhibitors (adverse effects)
• Neuroectodermal Tumors, Primitive (chemically induced)
• Maximum Tolerated Dose